封面
市场调查报告书
商品编码
1692334

兽医健康市场中的单株抗体 - 全球产业规模、份额、趋势、机会和预测,按动物类型、应用、最终用户、地区和竞争细分,2020-2030F

Monoclonal Antibodies In Veterinary Health Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type, By Application, End-User, By Region, & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球兽医保健单株抗体市场价值为 9.034 亿美元,预计在预测期内将实现令人印象深刻的成长,到 2030 年的复合年增长率为 15.50%。全球兽医保健单株抗体 (mAb) 市场代表了更广泛的动物保健产业中一个快速成长的领域。单株抗体是实验室设计的可以针对特定抗原的抗体,因其治疗和诊断应用而越来越多地被兽医学采用。

市场概况
预测期 2026-2030
2024 年市场规模 9.034亿美元
2030 年市场规模 21.4929亿美元
2025-2030 年复合年增长率 15.50%
成长最快的领域 皮肤科
最大的市场 北美洲

主要市场驱动因素

增加伴侣动物饲养量和宠物人性化

主要市场挑战

开发成本高

主要市场趋势

标靶治疗的扩展

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:顾客之声

第五章:全球兽医保健单株抗体市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依动物类型(狗、其他)
    • 依应用分类(皮肤病学、疼痛学、其他)
    • 按最终用户(兽医医院,其他)
    • 按地区
    • 按公司分类(2024)
  • 产品市场图
    • 依动物类型
    • 按应用
    • 按最终用户
    • 按地区

第 6 章:北美兽医保健单株抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 加拿大
    • 墨西哥

第 7 章:欧洲兽医保健单株抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章:亚太地区兽医保健单株抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 日本
    • 印度
    • 澳洲
    • 韩国

第九章:南美洲兽医保健单株抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲兽医保健单株抗体市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 科威特

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 近期发展
  • 合併与收购
  • 产品发布

第 13 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章:竞争格局

  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco LLC
  • Boehringer Ingelheim GmbH
  • Indian Immunologicals Ltd
  • Virbac SA

第 15 章:策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 17566

Global Monoclonal Antibodies In Veterinary Health Market was valued at USD 903.40 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 15.50% through 2030. The global monoclonal antibodies (mAbs) in veterinary health market represents a rapidly growing segment within the broader animal healthcare industry. Monoclonal antibodies, which are lab-engineered antibodies that can target specific antigens, are increasingly being adopted in veterinary medicine for their therapeutic and diagnostic applications.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 903.40 Million
Market Size 2030USD 2149.29 Million
CAGR 2025-203015.50%
Fastest Growing SegmentDermatology
Largest MarketNorth America

Key Market Drivers

Increasing Companion Animal Ownership and Pet Humanization

The increasing trend of companion animal ownership, coupled with the growing humanization of pets, is a major driver of the Global Monoclonal Antibodies (mAbs) in the Veterinary Health Market. Over 50% of the global population is estimated to own a pet, with dogs being the most prevalent, found in approximately 33% of households worldwide. Cats are the second most popular choice, owned by nearly 25% of pet-keeping households. This widespread pet ownership trend reflects a significant and growing market opportunity for pet-related industries, including food, healthcare, accessories, and services, driven by increasing consumer demand and the human-animal bond. As pet owners demand higher-quality healthcare solutions for their animals, the market for advanced veterinary therapeutics, including monoclonal antibody-based treatments, is experiencing significant growth.

Households in the U.S., EU, and China collectively own over 500 million dogs and cats, underscoring a massive and expanding market for pet healthcare solutions. In the U.S., pet ownership grew from 68% of households in 2016 to 70% in 2021, reflecting a sustained upward trend in companion animal adoption and increased consumer spending on veterinary care. Over the past decade, there has been a significant increase in pet adoption rates, particularly in developed economies such as North America, Europe, and parts of Asia-Pacific. Factors such as rising disposable incomes, changing lifestyles, and a growing preference for emotional companionship have contributed to this trend. With pet ownership on the rise, there is a corresponding increase in demand for effective veterinary treatments, including monoclonal antibodies for conditions such as arthritis, dermatological disorders, and cancer.

Key Market Challenges

High Development Costs

Developing monoclonal antibodies is a complex and expensive process. Research and development costs can be prohibitively high, which poses a significant challenge for smaller biotech companies and startups looking to enter the market. These high costs can limit the diversity of players and the range of mAb products available..

Key Market Trends

Expansion of Targeted Therapies

One of the most significant upcoming trends is the expansion of targeted therapies using monoclonal antibodies. As our understanding of animal diseases and their molecular mechanisms deepens, researchers are developing mAbs that can target specific disease pathways with precision. This trend promises to provide veterinarians with a broader range of effective treatment options for a variety of conditions.

Key Market Players

  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco LLC
  • Boehringer Ingelheim GmbH
  • Indian Immunologicals Ltd
  • Virbac SA

Report Scope:

In this report, the Global Monoclonal Antibodies In Veterinary Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monoclonal Antibodies In Veterinary Health Market, By Animal Type:

  • Dogs
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Application:

  • Dermatology
  • Pain
  • Others

Monoclonal Antibodies In Veterinary Health Market, By End-User:

  • Veterinary Hospitals
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibodies In Veterinary Health Market.

Available Customizations:

Global Monoclonal Antibodies In Veterinary Health market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monoclonal Antibodies In Veterinary Health Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Dogs, Others)
    • 5.2.2. By Application (Dermatology, Pain, Others)
    • 5.2.3. By End-User (Veterinary Hospitals, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Animal Type
    • 5.3.2. By Application
    • 5.3.3. By End-User
    • 5.3.4. By Region

6. North America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type (Dogs, Others)
    • 6.2.2. By Application (Dermatology, Pain, Others)
    • 6.2.3. By End-User (Veterinary Hospitals, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User

7. Europe Monoclonal Antibodies In Veterinary Health Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type (Dogs, Others)
    • 7.2.2. By Application (Dermatology, Pain, Others)
    • 7.2.3. By End-User (Veterinary Hospitals, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. United Kingdom Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. France Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. Asia-Pacific Monoclonal Antibodies In Veterinary Health Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type (Dogs, Others)
    • 8.2.2. By Application (Dermatology, Pain, Others)
    • 8.2.3. By End-User (Veterinary Hospitals, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. Japan Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. India Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User
    • 8.3.4. Australia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-User
    • 8.3.5. South Korea Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-User

9. South America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type (Dogs, Others)
    • 9.2.2. By Application (Dermatology, Pain, Others)
    • 9.2.3. By End-User (Veterinary Hospitals, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Monoclonal Antibodies In Veterinary Health Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type (Dogs, Others)
    • 10.2.2. By Application (Dermatology, Pain, Others)
    • 10.2.3. By End-User (Veterinary Hospitals, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User
    • 10.3.4. Kuwait Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Animal Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Zoetis Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offering
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (as reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Merck & Co., Inc.
  • 14.3. Elanco LLC
  • 14.4. Boehringer Ingelheim GmbH
  • 14.5. Indian Immunologicals Ltd
  • 14.6. Virbac SA

15. Strategic Recommendations

16. About Us & Disclaimer